

EXECUTIVE SUMMARY

Cancer is one of the leading public health challenges worldwide and is growing rapidly in Latin America and the Caribbean (LAC). The region reported over 4.2 million new cancer cases in 2022, a number projected to reach 6.7 million by 2045¹. Mortality rates remain high, with 1.4 million deaths only in 2022, nearly half occurring in people under 70 years old. Despite this growing burden, LAC populations remain almost absent from global tumor biobanks and clinical trial datasets, undermining the effectiveness of new therapies and widening inequities in cancer treatment outcomes.

[Biomakers](#), an Argentinian precision medicine and biotechnology company, addresses this gap by democratizing access to molecular profiling for oncology patients across LAC. The Company operates a comprehensive platform that integrates genomic diagnostics, biobanking, data infrastructure, and physician support tools. Through partnerships with hospitals and pharmaceutical companies, Biomakers provides free molecular diagnostics for advanced cancer patients, while generating the largest regional tumor biobank and genomic dataset in LAC.

Biomakers has expanded rapidly, establishing genomic laboratories in Argentina, Brazil, and Mexico, and creating a biobank of over 92,000 unique samples along with a dataset covering more than 70,000 patients across 17 countries. Its proprietary platform, PLUTON, combines clinical and molecular data, helping oncologists with actionable genomic reports and allowing pharmaceutical partners to access anonymized, customized datasets for oncology R&D. Biomakers' service offerings also include pre-screening programs for clinical trial enrollment and Biomakers Campus, an education platform for healthcare professionals.

The main beneficiaries of the Project are oncology patients in LAC, especially low-income individuals treated in public hospitals, who receive free genetic testing sponsored by the pharmaceutical industry. This eases the burden on overstretched public health systems and boosts survival rates for patients traditionally excluded from advanced treatments. Other stakeholders include oncologists, who gain access to advanced diagnostic tools, and pharmaceutical companies, which obtain access to diverse anonymized genomic data necessary for developing inclusive and effective cancer treatments therapies.

IDB Lab proposes an equity investment to support Biomakers' next growth phase, including consolidating its operations in Brazil and Mexico and expanding its genomic data platform and life sciences business unit. The investment aligns with IDB Lab's strategic priorities of improving access to quality healthcare, promoting inclusion in scientific research, and driving innovation in biotechnology across LAC. By assisting Biomakers' scale-up, IDB Lab will help reduce disparities in cancer treatment, increase regional participation in global oncology research, and foster the development of a more inclusive and effective healthcare ecosystem.

¹ PAN AMERICAN HEALTH ORGANIZATION. [Cancer](#). Washington, D.C.: PAHO, [n.d.].